Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
St. Jude Children's Research Hospital
Baylor College of Medicine
Emory University
Baylor College of Medicine
St. Jude Children's Research Hospital
Seattle Children's Hospital
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
Taipei Medical University
Pfizer